UNLIMITED TURBO LONG - ELI LILLY & CO | Real-time Euronext Paris 08:28:40 22/05/2024 pm IST | ||
| 3.771 EUR | -2.15% |
|
| Current month | +12.00% | ||
| 1 month | +49.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 22/24/22 | 3.771 | -2.15% |
| 21/24/21 | 3.854 | +12.95% |
| 20/24/20 | 3.412 | +6.09% |
| 17/24/17 | 3.216 | -3.42% |
| 16/24/16 | 3.33 | -1.25% |
Real-time Euronext Paris
Last update May 22, 2024 at 08:28 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| EV5NB | |
| ISIN | NLBNPNL2P1D2 |
| Date issued | 21/03/2024 |
| Strike | 611 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 3.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.052 € |
|---|---|
| Lowest since issue | 2.35 € |
| Spread | 0.024 € |
| Spread % | 0.63% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- EV5NB Certificat